...
首页> 外文期刊>Transplant international : >Strategies based on organ decellularization and recellularization
【24h】

Strategies based on organ decellularization and recellularization

机译:基于器官脱细胞化和流速化的策略

获取原文
获取原文并翻译 | 示例

摘要

Summary Transplantation is the only curative treatment option available for patients suffering from end‐stage organ failure, improving their quality of life and long‐term survival. However, because of organ scarcity, only a small number of these patients actually benefit from transplantation. Alternative treatment options are needed to address this problem. The technique of whole‐organ decellularization and recellularization has attracted increasing attention in the last decade. Decellularization includes the removal of all cellular components from an organ, while simultaneously preserving the micro and macro anatomy of the extracellular matrix. These bioscaffolds are subsequently repopulated with patient‐derived cells, thus constructing a personalized neo‐organ and ideally eliminating the need for immunosuppression. However, crucial problems have not yet been satisfyingly addressed and remain to be resolved, such as organ and cell sources. In this review, we focus on the actual state of organ de‐ and recellularization, as well as the problems and future challenges.
机译:总结移植是患有患者患有终级器官衰竭的患者的唯一疗法治疗选择,提高其生命质量和长期生存。然而,由于器官稀缺,只有少数这些患者实际上受益于移植。需要替代处理选项来解决这个问题。整个器官脱细胞化和透露式化技术在过去十年中引起了越来越长的关注。脱细胞化包括从器官中除去所有细胞组分,同时保留细胞外基质的微观和宏观解剖学。随后将这些BioscaffOlds与患者衍生的细胞重新灌注,从而构建个性化的新器官,理想地消除了对免疫抑制的需求。但是,尚未令人满意地讨论并仍有待解决的问题,例如器官和细胞来源。在本次审查中,我们专注于器官的实际状态,以及问题和未来的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号